In this article, we will look at the 10 Best Stocks to Buy in a Rising Market According to Wall Street Analysts.
The equity market remains bullish, driven by a record-setting trend fueled by renewed enthusiasm for artificial intelligence. Strong first-quarter earnings have also bolstered investor confidence despite soaring geopolitical tensions in the Middle East and inflationary pressures from higher oil prices.
The S&P 500 and tech-heavy Nasdaq 100 are back to record highs, affirming the bull market could persist into 2027. Similarly, Citigroup strategists have joined Wall Street peers in turning more constructive amid rising markets. According to strategists, elevated war uncertainty is supporting a renewed focus on higher-quality, defensive companies.
Citigroup strategists join their counterparts at BlackRock and Morgan Stanley in remaining confident about the resilience of the US market. They now expect the S&P 500 to reach 7,700 by year’s end. Goldman Sachs expects the S&P 500 to continue edging higher, as it has after episodes of geopolitical risk.
“While distribution of potential outcomes is wide, the macro headwinds in our base case outlook generally appear priced, the fundamental engine of earnings growth continues to run, and valuations — while still elevated relative to history — are less demanding than they were a few months ago,” Goldman’s Ben Snider wrote in a note.
Morgan Stanley strategist Michael Wilson insists markets have moved well in front of the risks that are now obvious. While the S&P 500 is up about 4% year to date and flirting with record highs, some stocks have outperformed the benchmark and still show significant upside amid renewed demand for risk in the market.
Our Methodology
To compile a list of the Best Stocks to buy in a Rising Market, according to Wall Street Analysts, we used the Finviz screener to identify stocks that have gained more than 20% year to date and are outperforming the overall market. We further trimmed the list to stocks with upside potential of more than 20% as of April 27. We also focused on stocks that are popular among elite hedge funds in Q4 2025. Finally, we ranked the stocks in ascending order by upside potential.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
Best Stocks to Buy in a Rising Market According to Wall Street Analysts
10. ASML Holding N.V. (NASDAQ:ASML)
Stock Upside Potential: 20.54%
Year to Date Gain: 26.70%
Number of Hedge Fund Holders: 101
ASML Holding N.V. (NASDAQ:ASML) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 15, Chief Executive Officer Christophe Fouquet reiterated that ASML Holding N.V. order intake remains strong as demand for chips continues to outpace supply, with customers accelerating capacity expansion.
Consequently, second-quarter net sales are expected to be between €8.4 billion and €9.0 billion, with a gross margin of 51%-52%. Full-year net sales are expected to be between €36 billion and €40 billion, with a gross margin of 51%-53%. The solid guidance comes against the backdrop of the company delivering first-quarter net sales of €8.8 billion, in line with guidance, net income of €2.8 billion, and a gross margin of 53%.
Following the impressive first- and second-quarter guidance, ASML Holding NV intends to declare a total dividend for 2025 of €7.50 per ordinary share, representing a 17% increase compared to 2024. In the first quarter, the company also returned value to shareholders by repurchasing €1.1 billion of shares.
ASML Holding N.V. is the world’s leading manufacturer of photolithography machines, which are critical, high-tech systems used by semiconductor companies (like TSMC, Intel, and Samsung) to print tiny circuit patterns onto silicon wafers, effectively creating microchips.
9. Devon Energy Corporation (NYSE:DVN)
Stock Upside Potential: 21.54%
Year To Date Gain: 26.59%
Number of Hedge Fund Holders: 50
Devon Energy Corporation (NYSE:DVN) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 11, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for the proposed merger of Devon Energy Corporation and Coterra Energy expired without objection. With the expiry, the proposed merger satisfies the key regulatory condition.
The proposed merger remains subject to customary closing conditions. The transaction is also expected to close in the second quarter. Devon Energy has already filed a registration statement on Form S-4 with the Securities and Exchange Commission for the registration of shares in connection with the merger.
Devon Energy Corp has rallied by more than 26% year to date, its market sentiment bolstered by the proposed merger with Coterra Energy. The merger will result in a large-cap oil and gas producer focused on the Permian Basin. Devon and Coterra are targeting $1 billion in annual pretax savings from the merger by 2027 and plan to reward investors with high dividends and share buybacks of more than $5 billion.
Devon Energy Corporation is an independent U.S.-based energy company. It focuses on the exploration, development, and production of oil, natural gas, and natural gas liquids (NGLs). The company specializes in horizontal drilling and hydraulic fracturing. Its core operations are in the Delaware Basin, Eagle Ford, Anadarko, Williston, and Powder River basins.
8. Forgent Power Solutions, Inc. (NYSE:FPS)
Stock Upside Potential: 22.37%
Year To Date Gain: 21.17%
Number of Hedge Fund Holders: N/A
Forgent Power Solutions, Inc. (NYSE:FPS) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 15, Barclays touted Forgent Power Solutions, Inc. as one of the top US electrical equipment stocks to own.
According to the investment bank, Forgent Power Solutions is one of the 400 companies well-positioned to benefit from the digital and power infrastructure build-out. Consequently, the company should capitalize on the build-out of artificial intelligence data centers as hyperscaler capital expenditure rises.
The company reported a 69% increase in its fiscal second-quarter 2026 revenues, asserting exceptional momentum across the business. The increase also underscored market growth and share gains in all the primary end markets. According to Chief Executive Officer Gary Niederpruem, demand for Forgent Power Solutions’ products continues to exceed expectations. Margins are also expected to expand in the third quarter and increase in the fourth quarter due to higher production volumes.
Forgent Power Solutions, Inc. is a leading U.S. designer and manufacturer of custom electrical distribution equipment, specializing in critical power infrastructure for data centers, the power grid, and energy-intensive industrial facilities.
7. BorgWarner Inc. (NYSE:BWA)
Stock Upside Potential: 23.02%
Year To Date Gain: 20.69%
Number of Hedge Fund Holders: 43
BorgWarner Inc. (NYSE:BWA) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 21, BorgWarner Inc. secured a seven-year contract extension to supply eight families of engine machine power modules and battery management system controllers.
The company is to supply the system controllers to a world-leading off-highway manufacturer through 2032. BorgWarner has supplied similar products to the manufacturer for several decades. The supply contract extensions come as the manufacturer tries to increase production volume across various market segments.
The seven-year contract extension builds on decades of partnership with the OEM and spans a broad range of Applications. The system controllers are to be used across construction vehicles, marine platforms, and stationary power systems.
The seven-year contract extensions affirm BorgWarner’s growing position as a propulsion partner in supporting manufacturers’ expansion into new markets.
BorgWarner Inc. is a global automotive supplier that designs and manufactures advanced components for combustion, hybrid, and electric vehicles (EVs). The company specializes in propulsion systems, including chargers, electric motors, inverters, and battery management systems.
6. Revolution Medicines, Inc. (NASDAQ:RVMD)
Stock Upside Potential: 26.47%
Year To Date Gain: 71.22%
Number of Hedge Fund Holders: 85
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 27, shares of Erasca dropped sharply after Revolution Medicines Inc. accused the company of infringing patents and misusing trade secrets tied to its cancer drug candidate ERAS-0015. Revolution claims the therapy is substantially similar to its own treatment and demanded that Erasca halt U.S. development, also alleging improper use of comparative data. While Erasca disputes the claims and plans to fight them, the dispute overshadowed positive early-stage trial results for ERAS-0015 and triggered a steep selloff in the stock.
On April 23, Mizuho reiterated an Outperform rating on Revolution Medicines Inc. shares (NASDAQ:RVMD) and raised the price target to $185 from $140.
The price target hike comes amid growing confidence about the company’s lead candidate drug, daraxonrasib, in the treatment of pancreatic cancer. The research firm has already increased the drug’s success probability to 90% from 80%, buoyed by recent clinical trial data. It has also accelerated the drug’s adoption trajectory as a first- and second-line treatment for pancreatic cancer.
Immediate first-line data showed landmark analyses at 6 months for the daraxonrasib regimen that were comparable to those of gemcitabine plus nab-paclitaxel. Mizuho remains optimistic about the ongoing RaSolute 303 study following daraxonrasib’s performance as a second-line treatment. It expects the drug to generate $14 billion in risk-adjusted pancreatic cancer revenues by 2035.
Revolution Medicines Inc. is a clinical-stage oncology company. It develops targeted therapies for patients with RAS-addicted cancers, which drive roughly 30% of human cancers. The company uses a proprietary tri-complex inhibitor platform to target active RAS proteins (RAS-ON inhibitors).
5. Venture Global, Inc. (NYSE:VG)
Stock Upside Potential: 34.03%
Year to Date Gain: 69.03%
Number of Hedge Fund Holders: 22
Venture Global Inc. (NYSE:VG) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 23, Venture Global Inc. subsidiary Venture Global Calcasieu closed a $750 million senior secured note pegged at 6% and due in 2036.
The notes are secured by a first-priority security interest in assets. The company plans to use net proceeds from the offering, along with cash on hand and other funds, to prepay outstanding term loans. Earlier on April 10, Calcasieu Pass Funding entered into a $1.75 billion senior secured term loan B credit facility.
The company used part of the proceeds from the credit facility to redeem in full the preferred equity interests previously issued to Stonepeak Bayou Holdings. The issuance of the $1.75 credit facility significantly reduced the overall cost of capital. It also further strengthened the balance sheet and liquidity position, and underscored Venture Global Inc.’s ability to access the capital markets even in a dynamic environment.
Venture Global, Inc. is a prominent American energy company. It develops, owns, and operates liquefied natural gas (LNG) export facilities using modular technology. This allows production of low-cost LNG from North American natural gas. The company focuses on the entire LNG supply chain, including production, transport, and export.
4. Circle Internet Group Inc. (NYSE:CRCL)
Stock Upside Potential: 38.14%
Year to Date Gain: 20.20%
Number of Hedge Fund Holders: 58
Circle Internet Group Inc. (NYSE:CRCL) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 22, Morgan Stanley reiterated an $80 price target and Equal Weight rating on Circle Internet Group Inc..
Morgan Stanley maintains an Equal Weight rating on the stock, citing the Decentralized Finance deregulation and industry players’ liability for illegal activity. Recent hacks at KelpDAO, where $290 million was stolen, and Drift Protocol, where $285 million was stolen, underscore headwinds in the industry. Additionally, the sector is under scrutiny as bank lobbying groups remain opposed to stablecoin yields, which they believe will cause deposit flight.
On the other hand, Circle Internet Group launched its Circle Payment Network Management Payments service. The service enabled banks and enterprises to use USDC stablecoin for transactions without directly managing digital assets. It also includes the minting and burning of blockchain infrastructure, allowing partners to interact solely in fiat currency.
Circle Internet Group is a financial technology company that provides infrastructure for digital currency and public blockchain, enabling businesses to move money efficiently. It is best known as the principal issuer and operator of USDC, a major dollar-pegged stablecoin, and as a provider of tools for programmable payments and blockchain applications.
3. Summit Therapeutics (NASDAQ:SMMT)
Stock Upside Potential: 42.05%
Year To Date Gain: 26.03%
Number of Hedge Fund Holders: 25
Summit Therapeutics (NASDAQ:SMMT) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 21, analysts at Stifel reiterated a Buy rating on Summit Therapeutics and a $45 price target.
The positive stance comes on the heels of Akeso announcing plans to disclose HARMONi-6 interim Overall Survival readout at ASCO 2026. The disclosure is to optimize the setup better than when HARMONi-2 interim OS was disclosed last year as a result of an NMPA approval.
Unlike Harmoni 2, Harmoni-6 features 33% larger sample size and all-squamous histology. The study provides a first look at an emerging OS from an ivonescimab Phase 3 trial randomized against anti-PD-1 tislelizumab. Last year, HARMONi-2 analyzed ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Akeso is seeking label expansion for Ivonescimab in China, following an interim analysis requested by Chinese health authorities that showed a clinically meaningful positive trend favoring Ivonescimab over Pembrolizumab in PD-L1.
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies to treat serious, unmet medical needs. Their primary focus is the development and commercialization of ivonescimab, a potential first-in-class bispecific antibody targeting PD-1 and VEGF for the treatment of non-small cell lung cancer (NSCLC).
2. Applied Digital Corporation (NASDAQ:APLD)
Stock Upside Potential: 42.94%
Year To Date Gain: 24.53%%
Number of Hedge Fund Holders: 40
Applied Digital Corporation (NASDAQ:APLD) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 8, Applied Digital Corporation asserted its differentiation in the high-power AI data center industry. The differentiation comes as the company operates the only 100MW direct-to-chip liquid-cooled data center.
The company delivered a 139% increase in fiscal third-quarter revenue to $126.6 million. Amid the robust revenue growth, the net loss attributable to shareholders reported was $100.9 million. The financial results came on the heels of accelerating demand for high-performance AI data center capacity.
In addition, Applied Digital Corp’s data center hosting business, which operates 286 MW of Bitcoin mining capacity, continues to deliver strong results and the highest return on assets. The segment generated $14 million in operating profit and $37.5 million in revenue in the quarter ended February. The solid performance was driven by improvements across data center hosting facilities.
Applied Digital Corporation designs, builds, and operates next-generation data centers and high-performance computing (HPC) infrastructure, primarily serving AI, machine learning, and cloud applications. The company provides turnkey hosting services and GPU-driven cloud services for artificial intelligence, while maintaining infrastructure for blockchain/Bitcoin.
1. ImmunityBio, Inc. (NASDAQ:IBRX)
Stock Upside Potential: 79.21%
Year To Date Gain: 268.32%
Number of Hedge Fund Holders: 19
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 9, ImmunityBio, Inc. delivered impressive preliminary operational results for its fiscal quarter ending March 31, 2026.
Product revenue in the quarter was up 168% year over year to $44.2 million. The increase comes on the heels of ANKTIVA, an FDA-approved treatment for non-muscle invasive bladder cancer, commercial launch. The significant product revenue builds on 2025 net product revenue of $113 million, a 700% increase over 2024. ImmunityBio exited the quarter with $380.9 million in cash and cash equivalents.
ANKTIVA is the company’s lead product, expected to solidify its revenue base as it has been approved across five jurisdictions representing 34 countries. Its continued momentum underscores growing physician adoption and disciplined commercial execution. Following strong growth in 2025, ImmunityBio is focused on scaling in the US and expanding into global markets to pursue new revenue streams.
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing and commercializing next-generation immunotherapies that activate a patient’s natural killer (NK) cells and T cells to treat cancers and infectious diseases. Its lead FDA-approved drug, ANKTIVA (N-803), is used in combination with BCG to treat non-muscle invasive bladder cancer (NMIBC).
READ NEXT: 11 Best TSX Stocks to Buy According to Hedge Funds and 8 Best Australian Stocks to Buy in 2026.
